CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Ginkgo biloba extract EGb 761drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00251238
NCT00251238Phase 2Completed
CompareCT.gov

Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon

VSM Geneesmiddelen b.v.·interventional·Posted Nov 9, 2005·Updated May 22, 2017

In Brief

A Phase 2 clinical trial evaluating Ginkgo biloba extract EGb 761 for Raynaud Disease. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRaynaud Disease
CountriesNetherlands
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 9, 2005
Enrollment StartNov 1, 2005
Primary CompletionMar 1, 2006
Study CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 20.6 years ago

Interventions

Ginkgo biloba extract EGb 761drug

daily Ginkgo biloba extract EGb 761